Figure 2 | Scientific Reports

Figure 2

From: Safety assessment, radioiodination and preclinical evaluation of antinuclear antibody as novel medication for prostate cancer in mouse xenograft model

Figure 2

Representative images of different tissues from mice in all groups that were stained with hematoxylin/eosin. No significant abnormalities were evident in any sections. a Group I, observed on Day 3 after injection; Control group (normal saline); 5 μg ANA-treated group (showed signs of inflammation and congestion, with the liver tissue showing congestion in 2/10 mice and inflammation in 2/10 mice). The spleen and heart exhibited congestion in 2/10 mice, and the lungs and kidneys exhibited congestion in 1/10 mice; 50 μg ANA-treated group (showed signs of congestion in 4/10 mice of each group); Group II, observed on Day 30 after injection; Control group (normal saline); 5 μg ANA-treated group (showed signs of inflammation in liver tissue in 1/10 mice); 50 μg ANA-treated group (1/10 mice showed cave-degraded hepatocytes, 1 mouse in each group showed light vein congestion); Ia, IIa: No significant abnormalities were evident in any sections. White arrow: Vein congestion. Gray arrow: Mild reactive inflammation with a cluster of lymphocytes. Black arrow: Cave-degraded hepatocytes.

Back to article page